Literature DB >> 28736229

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study.

Thomas K Eigentler1, Ulrike Leiter2, Hans-Martin Häfner2, Claus Garbe2, Martin Röcken2, Helmut Breuninger2.   

Abstract

Cutaneous squamous cell carcinoma (cSCC) is an increasing health burden in white populations. We prospectively assessed risk factors for tumor-specific and overall survival in 1,434 patients who underwent surgery for cSCC between January 24, 2005, and May 29, 2015. A total of 2,149 invasive cSCCs were analyzed. Univariate and multivariate survival analyses included tumor thickness, horizontal size, body site, histological differentiation, desmoplastic growth, history of multiple cSCCs, and immunosuppression. The primary endpoint was time to tumor-specific death. During a median follow-up period of 36.5 months (range = 0-137 months), 515 patients died; 40 because of cSCC (2.8%). Of those, 12 died because of visceral metastases and 28 because of tumor growth by local infiltration. On multivariate analyses, prognostic factors for tumor-specific survival were increased vertical tumor thickness (hazard ratio = 6.73; 95% confidence interval = 3.47-13.08; P < 0.0001), desmoplastic growth (hazard ratio = 4.14; 95% confidence interval = 2.68-9.83; P < 0.0001), and immunosuppression (hazard ratio = 2.07; 95% confidence interval = 1.04-4.12; P = 0.039). Defining a point list out of those factors and grouping them into four cohorts resulted in comprehensively separating survival curves (P < 0.001). Using a cut-off for tumor thickness of 6 mm or greater, the presence of desmoplastic growth and immunosuppression identifies patients at high risk for tumor-specific death.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28736229     DOI: 10.1016/j.jid.2017.06.025

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  25 in total

1.  Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women's Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma.

Authors:  Emily Stamell Ruiz; Pritesh S Karia; Robert Besaw; Chrysalyne D Schmults
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

2.  Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.

Authors:  Abby R Rosenberg; Mary Tabacchi; Kenneth H Ngo; Michael Wallendorf; Ilana S Rosman; Lynn A Cornelius; Shadmehr Demehri
Journal:  JCI Insight       Date:  2019-03-21

Review 3.  [Classification of cutaneous squamous cell carcinoma : How do I recognise my high-risk patient?]

Authors:  Lukas Kofler
Journal:  Hautarzt       Date:  2019-11       Impact factor: 0.751

4.  Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers.

Authors:  Michele Guida; Pietro Quaglino; Paola Queirolo
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

5.  Impact of COVID-19 Pandemic on Non-Melanoma Skin Cancer's Tumor Burden and Care: a Multi-Center Study Based in Northern Italy.

Authors:  Cozzi Silvia; Codazzi Denis; Cherubino Mario; Valdatta Luigi; Tamborini Federico; Carminati Marcello
Journal:  J Plast Reconstr Aesthet Surg       Date:  2022-06-22       Impact factor: 3.022

6.  Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery).

Authors:  Alejandra Tomás-Velázquez; Onofre Sanmartin-Jiménez; Joan R Garcés; Manuel A Rodríguez-Prieto; Verónica Ruiz-Salas; Esther De Eusebio-Murillo; Román Miñano-Medrano; Begoña Escutia-Muñoz; Ángeles Flórez-Menéndez; Juan L Artola-Igarza; Alberto Alfaro-Rubio; Pilar Gil; Yolanda Delgado-Jiménez; Julia M Sanchez-Schmidt; Irati Allende-Markixana; María L Alonso-Pacheco; Beatriz García-Bracamonte; Pablo De la Cueva-Dobao; Raquel Navarro-Tejedor; Cristina Ciudad-Blanco; Lucía Carnero-González; Hugo Vázquez-Veiga; Natividad Cano-Martínez; Eva Vilarrasa-Rull; Pedro Sanchez-Sambucety; José L López-Estebaranz; Rafael Botella-Estrada; Beatriz Gonzalez-Sixto; Antonio Martorell-Calatayud; Victoriano Morales-Gordillo; Agustí Toll-Abelló; Izascun Ocerin-Guerra; Matías Mayor-Arenal; Ricardo Suárez-Fernández; Laura Sainz-Gaspar; Miguel A Descalzo; Ignacio García-Doval; Pedro Redondo
Journal:  Acta Derm Venereol       Date:  2021-11-24       Impact factor: 3.875

Review 7.  Update of advanced cutaneous squamous cell carcinoma.

Authors:  E de Jong; M U P A Lammerts; R E Genders; J N Bouwes Bavinck
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-01       Impact factor: 9.228

Review 8.  Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.

Authors:  Brian C Baumann; Kelly M MacArthur; Jerry D Brewer; William M Mendenhall; Christopher A Barker; Jeremy R Etzkorn; Nathaniel J Jellinek; Jeffrey F Scott; Hiram A Gay; John C Baumann; Farrin A Manian; Phillip M Devlin; Jeff M Michalski; Nancy Y Lee; Wade L Thorstad; Lynn D Wilson; Carlos A Perez; Christopher J Miller
Journal:  Cancer       Date:  2020-06-01       Impact factor: 6.860

9.  Line-field confocal optical coherence tomography for actinic keratosis and squamous cell carcinoma: a descriptive study.

Authors:  E Cinotti; L Tognetti; A Cartocci; A Lamberti; S Gherbassi; C Orte Cano; C Lenoir; G Dejonckheere; G Diet; M Fontaine; M Miyamoto; J Perez-Anker; V Solmi; J Malvehy; V Del Marmol; J L Perrot; P Rubegni; M Suppa
Journal:  Clin Exp Dermatol       Date:  2021-09-24       Impact factor: 4.481

Review 10.  Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas.

Authors:  Sean R Christensen
Journal:  F1000Res       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.